Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M
- Development stage
- Approved
- Lead developer
- Novavax
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M is a protein subunit (recombinant nanoparticle) vaccine developed by Novavax and commercialized in partnership with Sanofi. It is designed to prevent COVID-19 caused by SARS-CoV-2, specifically targeting various Omicron subvariants (such as XBB.1.5 and JN.1). The vaccine consists of recombinant full-length, stabilized prefusion SARS-CoV-2 spike glycoproteins formulated with Novavax's proprietary saponin-based Matrix-M adjuvant to enhance and broaden the immune response. It is administered as an intramuscular injection and is indicated for active immunization in individuals aged 12 years and older, particularly those at high risk for severe COVID-19.
- Brand names
- CovovaxNuvaxovid
- Other names
- Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula)Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula)Nuvaxovid XBB.1.5SARS-CoV-2 recombinant spike protein nanoparticle vaccine adjuvanted with Matrix-MSARS-CoV2 recombinant spike protein nanoparticle vaccine adjuvanted with Matrix-MSARS-CoV 2 recombinant spike protein nanoparticle vaccine adjuvanted with Matrix-Msars-cov-2 (covid-19) nvx-cov2601 vaccine, adjuvantedsars-cov-2 (covid-19) nvx-cov2705 vaccine, adjuvanted
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M.